<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:hpo ids='HP_0011675'>cardiac arrhythmias</z:hpo> are commonly observed in the fetus, however, may have major consequences for fetal development and post natal life </plain></SENT>
<SENT sid="1" pm="."><plain>AIMS: to evaluate the perinatal management and cardiac outcome of fetuses with tachy- or <z:e sem="disease" ids="C0079035" disease_type="Disease or Syndrome" abbrv="">bradyarrhythmia</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>STUDY DESIGN: perinatal management, outcome and long-term cardiac follow-up were evaluated retrospectively in consecutive fetuses with <z:hpo ids='HP_0011675'>cardiac arrhythmias</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: forty-four fetuses were diagnosed: <z:hpo ids='HP_0004755'>supraventricular tachycardia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVT</z:e>, n=28), <z:hpo ids='HP_0004749'>atrial flutter</z:hpo> (AF, n=7) and <z:hpo ids='HP_0001678'>atrioventricular block</z:hpo> (AVB, n=9) </plain></SENT>
<SENT sid="4" pm="."><plain>The overall incidence of <z:hpo ids='HP_0001627'>cardiac anomalies</z:hpo> was 18% mainly in the AVB group; <z:hpo ids='HP_0000969'>hydrops</z:hpo> was present in 34% </plain></SENT>
<SENT sid="5" pm="."><plain>Direct or transplacental fetal anti-arrhythmic medication was given in 76% </plain></SENT>
<SENT sid="6" pm="."><plain>Mortality was 6% in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVT</z:e>/AF and 78% in the AVB group, respectively </plain></SENT>
<SENT sid="7" pm="."><plain>AF resolved in <z:hpo ids='HP_0000001'>all</z:hpo> patients </plain></SENT>
<SENT sid="8" pm="."><plain>In the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVT</z:e> group, <z:e sem="disease" ids="C0043202" disease_type="Disease or Syndrome" abbrv="wpw">Wolff-Parkinson-White (WPW) syndrome</z:e> was present in 21%, diagnosed at birth or later in life </plain></SENT>
<SENT sid="9" pm="."><plain>After the age of one year about 90% of patients in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVT</z:e> group remained asymptomatic and free of drugs (median follow-up 76months) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: mortality rate is low in patients with fetal <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVT</z:e> and AF but high in patients with AVB </plain></SENT>
<SENT sid="11" pm="."><plain>Related morbidity includes <z:e sem="disease" ids="C0043202" disease_type="Disease or Syndrome" abbrv="wpw">WPW-syndrome</z:e> and congenital <z:hpo ids='HP_0001627'>cardiac anomalies</z:hpo> </plain></SENT>
<SENT sid="12" pm="."><plain>Electrocardiographic screening is recommended in <z:hpo ids='HP_0000001'>all</z:hpo> fetal <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SVT</z:e> cases before adolescence since <z:e sem="disease" ids="C0043202" disease_type="Disease or Syndrome" abbrv="wpw">WPW-syndrome</z:e> may occur later in life </plain></SENT>
</text></document>